Coherus BioSciences, Inc. (CHRS) Bundle
Ever wondered how a biopharmaceutical company navigates the complex world of cancer immunotherapies? Coherus BioSciences, Inc. (CHRS), a commercial-stage company, has been making strategic moves to solidify its position in the market, but how exactly does it operate and generate revenue? With a recent focus on oncology and the divestiture of its UDENYCA® franchise to Intas Pharmaceuticals for up to $558.4 million, including an upfront payment of $483.4 million, Coherus is poised for a new chapter, so keep reading to find out more.
Coherus BioSciences, Inc. (CHRS) History
Founding Timeline
Year established
The company was established in 2010.
Original location
The company is headquartered in Redwood City, California.
Founding team members
The founding team included:
- Denny Lanfear
- Doug Treat
Initial capital/funding
In 2011, the company completed a Series A financing round, raising $55 million.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2012 | Filed its first biosimilar application in Europe. | Marked the company's initial steps into the global biosimilar market. |
| 2014 | Initiated a global Phase 3 clinical trial for its lead biosimilar candidate. | Demonstrated commitment to rigorous clinical development. |
| 2017 | U.S. Food and Drug Administration (FDA) approved UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®. | First product approval, marking a significant milestone in bringing biosimilar medicines to patients. |
| 2018 | Launched UDENYCA® in the U.S. | Began commercializing its first approved product. |
| 2022 | FDA approved CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®. | Expanded its portfolio with another key biosimilar approval. |
| 2023 | Acquired Surface Oncology. | Expanded into the oncolytic space. |
Transformative Moments
- FDA Approval of UDENYCA® (2018): This marked the transition from a development-stage company to a commercial entity, establishing its presence in the U.S. biosimilar market.
- Acquisition of Surface Oncology (2023): Diversified the company's portfolio beyond biosimilars into innovative oncology therapeutics, signaling a strategic shift towards novel treatments.
- Focus on Biosimilars: The company's strategic focus on biosimilars has allowed it to capitalize on the growing demand for affordable biologic therapies, establishing a strong foothold in the pharmaceutical industry.
To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Coherus BioSciences, Inc. (CHRS).
Coherus BioSciences, Inc. (CHRS) Ownership Structure
Coherus BioSciences, Inc. features a mixed ownership structure, including institutional, retail, and insider stakeholders, influencing its governance and strategic decisions.
Coherus BioSciences, Inc.'s Current Status
As of April 2025, Coherus BioSciences, Inc. is a publicly traded company, listed on the Nasdaq Global Select Market under the ticker symbol CHRS.
Coherus BioSciences, Inc.'s Ownership Breakdown
Understanding the ownership structure of Coherus BioSciences provides insights into who has influence over the company's decisions. Here's a breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutions | 97.84% | Institutional investors are major holders of Coherus BioSciences' stock. Top institutional holders include BlackRock Fund Advisors, Vanguard Group Inc, and State Street Corp. |
| Insiders | 0.44% | Company insiders, such as executives and board members, also hold a small percentage of the company's stock. These holdings can align management's interests with those of shareholders. |
| Retail Investors | 1.72% | Retail investors hold a minority stake in Coherus BioSciences. |
To gain a deeper understanding of the company's financial standing, explore Breaking Down Coherus BioSciences, Inc. (CHRS) Financial Health: Key Insights for Investors.
Coherus BioSciences, Inc.'s Leadership
The leadership team is crucial to the direction and success of Coherus BioSciences. Key figures include:
- Denny Lanfear: Chairman of the Board
- Rosh Dias, M.D.: Interim Chief Executive Officer
- McDavid Stilwell: Chief Financial Officer
These individuals, along with other members of the executive team, guide the company's strategic initiatives and operational execution.
Coherus BioSciences, Inc. (CHRS) Mission and Values
The company's mission is to improve patient lives by developing and commercializing innovative and biosimilar products, while its values emphasize integrity, collaboration, innovation, and a patient-centric approach.
Coherus BioSciences, Inc.'s Core Purpose
Official mission statement
The official mission statement is: 'To improve patient lives by developing and commercializing high-quality, innovative and biosimilar therapeutics that address significant unmet medical needs.'
- Focuses on enhancing patient well-being through therapeutic advancements.
- Highlights the development and commercialization of both innovative and biosimilar products.
- Aims to tackle unmet medical needs with high-quality solutions.
Vision statement
While a specific, formally declared vision statement is not prominently featured in recent official communications, the company's strategic actions and stated goals suggest a vision focused on:
- Becoming a leading innovator in the biosimilar and novel therapeutics market.
- Expanding its portfolio to address a broader range of therapeutic areas.
- Delivering significant value to patients, healthcare providers, and shareholders.
Company slogan/tagline
The business does not have a widely publicized official slogan or tagline. However, considering their focus, a potential implied tagline could be:
- 'Committed to Innovation, Dedicated to Patients.'
- 'Advancing Therapeutics, Improving Lives.'
To learn more about the investors, read this article: Exploring Coherus BioSciences, Inc. (CHRS) Investor Profile: Who’s Buying and Why?
Coherus BioSciences, Inc. (CHRS) How It Works
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company that specializes in developing and commercializing biosimilar and innovative medicines. The company aims to provide access to high-quality, cost-effective therapeutics, primarily focusing on oncology and immunology.
Coherus BioSciences' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Udenyca (pegfilgrastim-cbqv) | Cancer patients undergoing chemotherapy | A biosimilar to Neulasta, used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. |
| Cimerli (ranibizumab-eqrn) | Patients with neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization | A biosimilar to Lucentis, an anti-VEGF therapy used to treat several retinal diseases. |
| Yusimry (adalimumab-aqvh) | Patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis | A biosimilar to Humira, a tumor necrosis factor (TNF) blocker used to treat autoimmune diseases. |
| Loqtorzi (toripalimab-tpzi) | Adults with recurrent, or metastatic nasopharyngeal carcinoma (NPC) | A monoclonal antibody targeting the programmed cell death protein 1 (PD-1). |
Coherus BioSciences' Operational Framework
Coherus BioSciences operates through a structured framework that integrates development, manufacturing, and commercialization to deliver its products to market.
- Product Development: Coherus focuses on developing biosimilars and innovative therapies, with a strong emphasis on clinical trials and regulatory approvals.
- Manufacturing: The company partners with established manufacturers to produce its biosimilars and other products. These partnerships ensure product quality and scalability.
- Commercialization: Coherus has its own commercial infrastructure to market and sell its products in the United States. This includes sales, marketing, and distribution teams.
- Strategic Partnerships: Coherus collaborates with other companies to expand its product offerings and market reach.
Coherus BioSciences' Strategic Advantages
Coherus BioSciences has several strategic advantages that enable it to compete effectively in the biopharmaceutical industry.
- Biosimilar Expertise: Coherus has deep expertise in developing and commercializing biosimilars, allowing it to bring more affordable versions of existing drugs to market.
- Oncology Focus: With a strong focus on oncology, Coherus addresses a critical need for cost-effective cancer treatments.
- Established Commercial Infrastructure: Coherus has a well-established commercial infrastructure in the United States, which allows it to effectively market and sell its products.
- Strategic Collaborations: The company's strategic collaborations expand its product offerings and market reach, enhancing its competitive position.
More insights about Coherus BioSciences can be found here: Mission Statement, Vision, & Core Values of Coherus BioSciences, Inc. (CHRS).
Coherus BioSciences, Inc. (CHRS) How It Makes Money
Coherus BioSciences primarily generates revenue through the sale of its biosimilar products, which are approved versions of originator biologic drugs whose patents have expired. These biosimilars offer cost-effective alternatives, driving sales volumes and contributing to the company's financial performance.
Coherus BioSciences, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Udenyca | Approximately 66% | Decreasing |
| Biosimilars (excluding Udenyca) | Approximately 34% | Increasing |
Coherus BioSciences, Inc.'s Business Economics
Coherus BioSciences operates in the competitive biosimilars market, focusing on developing and commercializing cost-effective alternatives to high-priced biologic drugs. The company's business economics are influenced by several factors:
- Pricing Strategy: Coherus typically prices its biosimilars at a discount compared to the originator biologics. This discount attracts price-sensitive customers, including healthcare providers and payers, driving market share and sales volume.
- Cost of Goods Sold (COGS): Managing COGS is crucial for maintaining profitability. Coherus focuses on efficient manufacturing processes and strategic partnerships to reduce production costs and improve gross margins.
- Research and Development (R&D) Expenses: A significant portion of Coherus's expenses is allocated to R&D activities. These investments support the development of new biosimilars and the expansion of the company's product pipeline.
- Sales and Marketing Expenses: Effective sales and marketing strategies are essential for promoting product adoption and gaining market share. Coherus invests in targeted marketing campaigns and collaborations with healthcare providers to drive sales growth.
Coherus BioSciences, Inc.'s Financial Performance
Coherus BioSciences' financial performance reflects its ability to generate revenue, manage expenses, and achieve profitability in the biosimilars market.
- In 2024, Coherus BioSciences reported total revenues of $242.4 million, a 20.1% decrease compared to $303.6 million in 2023.
- The decrease was attributed to reduced net sales of UDENYCA, which fell from $243.7 million in 2023 to $159.1 million in 2024.
- Net product revenues for 2024 were $241.3 million, including $159.1 million from UDENYCA, $39.8 million from YUSIMRY, $22.6 million from CIMERLI, and $19.8 million from LOQTORZI.
- Research and development expenses for 2024 totaled $103.9 million, down from $123.9 million in 2023.
- Selling, general, and administrative expenses for 2024 were $149.1 million, compared to $173.4 million in 2023.
- The net loss for 2024 was $138.3 million, or $1.75 per share, compared to a net loss of $134.7 million, or $1.83 per share, for 2023.
To gain a deeper understanding of the financial health and strategic positioning of Coherus BioSciences, Inc., consider exploring further insights: Breaking Down Coherus BioSciences, Inc. (CHRS) Financial Health: Key Insights for Investors
Coherus BioSciences, Inc. (CHRS) Market Position & Future Outlook
Coherus BioSciences is navigating a competitive biopharmaceutical landscape, focusing on biosimilars and innovative immuno-oncology therapeutics. The company aims to strengthen its market position through strategic product development and commercialization, while also addressing challenges inherent in the industry. For more insights into the financial health of Coherus BioSciences, see: Breaking Down Coherus BioSciences, Inc. (CHRS) Financial Health: Key Insights for Investors
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Coherus BioSciences | ~3-5% (estimated) | Specialization in biosimilars and immuno-oncology with a focus on cost-effective therapeutics. |
| Amgen | ~20-25% (estimated) | Extensive portfolio of innovative and biosimilar products with a well-established global presence. |
| Sandoz | ~15-20% (estimated) | Strong focus on generic and biosimilar medicines, leveraging a broad global distribution network. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding biosimilar portfolio to capture a larger share of the market as patents for originator biologics expire. | Intense competition from established pharmaceutical companies and other biosimilar manufacturers. |
| Strategic partnerships and acquisitions to broaden product offerings and market reach. | Regulatory hurdles and delays in the approval process for new drugs and biosimilars. |
| Growing demand for cost-effective treatment options, driving increased adoption of biosimilars. | Pricing pressures and reimbursement challenges from healthcare providers and payers. |
Industry Position
Coherus BioSciences holds a strategic position within the biopharmaceutical industry, particularly in the rapidly evolving biosimilars market.
- Focus on biosimilars provides a pathway to address the increasing demand for affordable medicines.
- Development of innovative immuno-oncology therapies diversifies the portfolio and targets high-growth therapeutic areas.
- Commitment to strategic collaborations enhances research and development capabilities and expands market access.
Coherus BioSciences, Inc. (CHRS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.